AFMD Earnings

AFMD reported its FY2024Q2 earnings on 2024-09-05, showcasing a revenue of 154.00K against an estimate of 1.15M, resulting in a -86.65% surprise. The EPS was -1.09, surpassing the expected -1 by -9% . The stock experienced a 1.07% price change on the earnings day and a 2.67% change over the next five days, reflecting market reactions to the results.

Following AFMD's FY2024Q2 earnings announcement on 2024-09-05, the stock price moved by 1.07% on the day of the release. Over the subsequent five days, it saw a 2.67% change. Historically, AFMD's stock price tends to shift by an average of +1.51% in the 10 days leading up to earnings and +1.98% in the 10 days following, providing insight into potential market.

For 2024/Q4, analysts estimate AFMD’s annual revenue to reach 118.33K, while the EPS is projected at -0.86. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between AFMD's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2024 were No Change by 0%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, AFMD's stock price typically moves by +1.51% in the 10 days before its earnings and +1.98% in the 10 days after. For the upcoming 2024/Q4 earnings, analysts expect an EPS of -0.86 and revenue of 118.33K.

The earnings call summary shows a decrease in revenue and cash position, despite reduced expenses and net loss. The Q&A section highlights uncertainties regarding AFM28's FDA path, collaboration strategies, and data maturity. These factors, combined with unclear management responses, suggest investor concerns. The lack of strong positive catalysts and the ongoing financial challenges lead to a negative sentiment, predicting a stock price decrease of -2% to -8%.